HER1 and HER2 are clinically validated targets in several cancers, such as squamous cell carcinoma of the head and neck [23], colorectal [24], breast [25], gastric [26], brain [27], and non–small cell lung cancers [28]. This evidence concerns the gene ERBB2 and lung cancer.